Menopause publishes cBHT meta-analysis

A paper co-authored by APC board member A.J. Day, “Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women” was published Thursday in Menopause: Journal of The North American Menopause Society.

Although limited in scope, its unambiguous conclusion: There is no evidence that compounded hormones pose an increased clinical risk compared to FDA-approved products.

Sound familiar? We covered a pre-release of the paper in February; you can read the details here.